Invion (ASX:IVX) said the first patient was administered a dose of its topical formulation of its drug candidate, INV043, formulation of its lead drug candidate, INV043 in an open label Phase I/II trial for non melanoma skin cancer (NMSC), according to a Friday filing with the Australian bourse.
The open-label trial evaluates the safety and efficacy of INV043 for photodynamic cancer therapy, the filing said.
A safety review committee will assess whether to adjust the dose-light interval or expand the trial, the filing added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。